Arrayit Corporation (ARYC) leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. - Powerful Science for Life
Corporate - Media & Press - Press Release
Dr. Schena receives publication award.
Sunnyvale, CA, January 21, 2003 – On January 10th, Thomson Corporation, the world’s leading information resource, announced that TeleChem’s Visiting Scholar Dr. Mark Schena published the most highly cited scientific paper in the history of his field. Thomson’s ISI Division tracks scientific research papers as an indicator of their scientific impact.
The Essential Science Indicators chose a number of important research areas including the Arabidopsis field, which published Dr. Schena’s pioneering Science paper on microarrays. In the study, a total of 18,180 papers from 722 scientific journals, representing 29,339 authors in 83 countries and 3,272 institutions were assembled and ranked according to the number of journal citations over a ten year period spanning 1992-2002. Dr. Schena’s paper “Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray” published in Science magazine in 1995 (Science 270, 467-470) received a total of 1,287 citations, ranking it number one among the 18,180 papers examined. The next closest publications from the INRA in France, the California Institute of Technology in Pasadena, and Harvard Medical School in Boston received 722, 535 and 529 citations, respectively.
“This is a totally unexpected award”, said Dr. Schena. “We knew that the paper was well received, but to be rated number one among so many fine publications is simply amazing. This is a great day for the Arabidopsis field, microarrays and TeleChem. The entire Stanford research team deserves praise for this accomplishment.”
TeleChem International is a privately owned high-tech company located in the heart of California’s Silicon Valley. Our products and services are provided by three corporate divisions: ArrayIt® Life Sciences Division, Chemicals Division, and a Diagnostics Division. The ArrayIt® Life Sciences Division offers a complete microarray technology platform that empowers >10,000 laboratories to use microarrays for human genome exploration, basic research, drug discovery, and myriad life sciences applications. Nearly every major research institution uses our patented microarray manufacturing technology (U.S. 6,101,946) and supporting products and services. The Chemicals Division provides import and export services and government contract manufacturing in the area of industrial chemicals for plastics, fire control, water treatment, agriculture, industrial and institutional compounding, and green energy. The Diagnostics Division holds key patents in the United States (6,913,879), Singapore (94899), New Zealand (523560), and other countries for its revolutionary “multi-patient” genotyping technology, which allows as many as 100,000 patients to be tested on a single microarray. Arrayit Diagnostics enables genotyping and disease diagnostics by providing testing kits, services, and technology transfer opportunities for disease screening and testing organizations.
Copyright 1993-2019 Arrayit Corporation. All rights reserved.